| Name | Title | Contact Details |
|---|---|---|
David Nichols |
Chief Technical Officer | Profile |
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
Verdezyne, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We partner with exceptional scientists to bring a new class of medicines to patients in need, built around understanding the deep science of the “Nine Hallmarks of Aging” with the potential to both treat and prevent today`s deadliest diseases.
Novartis Animal Health, US is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.